dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Jones, Robin L. |
dc.contributor.author | Serrano Garcia, César |
dc.contributor.author | von Mehren, Margaret |
dc.contributor.author | Heinrich, Michael C. |
dc.contributor.author | Kang, Yoon-Koo |
dc.contributor.author | George, Suzanne |
dc.date.accessioned | 2021-07-05T08:27:28Z |
dc.date.available | 2021-07-05T08:27:28Z |
dc.date.issued | 2021-03 |
dc.identifier.citation | Jones RL, Serrano C, von Mehren M, George S, Heinrich MC, Kang YK, et al. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer. 2021 Mar;145:132-142. |
dc.identifier.issn | 0959-8049 |
dc.identifier.uri | https://hdl.handle.net/11351/6119 |
dc.description | Avapritinib; Tumors de l'estroma gastrointestinal; PDGFRA |
dc.description.sponsorship | The NAVIGATOR study (NCT02508532) was supported by Blueprint Medicines Corporation, Cambridge, Massachusetts, USA. |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | European Journal of Cancer;145 |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Mutació (Biologia) |
dc.subject | Inhibidors enzimàtics - Ús terapèutic - Eficàcia |
dc.subject | Aparell digestiu - Càncer |
dc.subject.mesh | Gastrointestinal Stromal Tumors |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Mutation |
dc.subject.mesh | Treatment Outcome |
dc.title | Avapritinib in unresectable or metastatic PDGFRA D842V - mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.ejca.2020.12.008 |
dc.subject.decs | tumores del estroma gastrointestinal |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | mutación |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://linkinghub.elsevier.com/retrieve/pii/S0959804920314234 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Jones RL] Royal Marsden Hospital and Institute of Cancer Research, London, UK. [Serrano C] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [von Mehren M] Fox Chase Cancer Center, Philadelphia, PA, USA. [George S] Dana-Farber Cancer Institute, Boston, MA, USA. [Heinrich MC] Portland VA Health Care System and OHSU Knight Cancer Institute, Portland, OR, USA. [Kang YK] Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea |
dc.identifier.pmid | 33465704 |
dc.identifier.wos | 000625301200013 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |